Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: Vertex, NHS England Reach Agreement on Pricing and Public Availability of CF Treatments CF Patients Voice Hopes and Expectations for Trikafta in Instagram Poll Vertex, NHS England Reach Agreement on Pricing and Public Availability of CF Treatments Oct 28, 2019 07:00 am | Iqra Mumal MSc Vertex Pharmaceuticals has reached an agreement with England’s National Health Service (NHS), allowing patients there access to all Vertex cystic fibrosis (CF) treatments currently approved in Europe at low or no out-of-pocket cost. The agreement between the NHS and Vertex appears to end a long-standing dispute over the company’s pricing — years in the case of Orkambi (lumacaftor/ivacaftor) […] The post Vertex, NHS England Reach Agreement on Pricing and Public Availability of CF Treatments appeared first on Cystic Fibrosis News Today. Read More CF Patients Voice Hopes and Expectations for Trikafta in Instagram Poll Oct 25, 2019 12:00 pm | Grace Frank A majority of cystic fibrosis patients who took part in an Instagram poll by BioNews Services said they would be interested in moving from current treatments to Trikafta (elexacaftor, tezacaftor, and ivacaftor), the newly approved and “next-generation” combination therapy by Vertex that is expected to treat 90% of all with CF. Among those now using Symdeko (tezacaftor/ivacaftor, ivacaftor) or Orkambi (lumacaftor/ivacaftor), two earlier […] The post CF Patients Voice Hopes and Expectations for Trikafta in Instagram Poll appeared first on Cystic Fibrosis News Today. Read More Recent News CF Mutation Carriers Have Increased Risk for Gastrointestinal Problems, Large-scale Study Finds Cystic Fibrosis Foundation Applauds FDA Approval of Trikafta Europe’s CHMP Issues Positive Opinion on Kalydeco Use in Infants Sick Food Diaries: A Day In the Life FDA Approves Trikafta, 1st Vertex Triple Combo with Potential to Treat 90% of CF Patients